March 15, 2005 09:00 ET

Nymox Reports 2004 Financial Results




MARCH 15, 2005 - 09:00 ET

Nymox Reports 2004 Financial Results

MAYWOOD, N.J.--(CCNMatthews - Mar 15, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its
financial results for the year ended December 31, 2004. Nymox reported a
narrowing of net loss by 17%, to $3,745,625, or $0.15 per share,
compared to $4,354,288, or $0.18 per share for 2003. The weighted,
diluted average number of common shares at December 31, 2004 was
25,103,252, compared to 23,771,858 at December 31, 2003. Product sales
increased by 62% and amounted to $321,895 for 2004, compared to $199,217
for 2003. Nymox currently has $11.76 million in financing available from
its most recent October 6, 2004 financing.

"The Company has strongly added to shareholder value in a highly
productive year in which many solid milestones were made, while our burn
rate was minimal by industry standards," said Paul Averback, CEO and
President of Nymox.

Nymox Pharmaceutical Corporation is a biopharmaceutical company with
three unique proprietary products on the market, and a significant R&D
pipeline of drug products in development. Nymox developed and is
currently offering its AlzheimAlert™ test, a nationally certified
clinical reference laboratory urinary test that is the world's only
accurate, non-invasive aid in the diagnosis of Alzheimer's disease. The
AlzheimAlert™ test is certified with a CE Mark, making the device
eligible for sale in the European Union. Nymox has signed a distribution
deal in Italy for AlzheimAlert™ with Alifax S.p.A.. Nymox also
developed and markets NicAlert™ and TobacAlert™; tests that use
urine or saliva to detect use of and exposure to tobacco products.
NicAlert™ has received clearance from the U.S. Food and Drug
Administration (FDA). TobacAlert™ is the first test of its kind to
accurately measure second hand smoke exposure in individuals. The
Company's TobacAlert™ product is presently available in CVS /
Pharmacy stores across the U.S.

Nymox is developing NX-1207, a novel treatment for benign prostatic
hyperplasia. NX-1207 has shown statistically significant positive
results in Phase 1 and 2 clinical trials in the U.S. NX-1207 is
currently in Phase 2 human testing in the US. Nymox also has several
other drug candidates and diagnostic technologies in development. Nymox
has U.S. and global patent rights for the use of statin drugs for the
treatment and prevention of Alzheimer's disease. The Company is
developing new antibacterial agents for the treatment of urinary tract
and other bacterial infections in humans and for the treatment of E.
coli O157:H7 contamination in meat and other food and drink products.
Nymox also is developing drug treatments aimed at the causes of
Alzheimer's disease. One program targets spherons, which Nymox
researchers believe are a source of the senile plaques found in the
brains of patients with Alzheimer's disease. Another distinct program
targets the brain protein (neural thread protein) detected by its
AlzheimAlert™ test and implicated in widespread brain cell death seen
in Alzheimer's disease.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. Such factors are detailed from time to time in
Nymox's filings with the United States Securities and Exchange
Commission and other regulatory authorities.


Contact Information

    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX